Biomind Labs Inc. announced positive results from in vivo studies. Biomind Labs' BMND07 drug candidate, a novel DMT combination drug, proved to be physiologically safe, showing low acute oral toxicity and no mutagenic effect in all administered dosages in animals.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1633 USD | +43.12% |
|
+43.12% | +63.30% |
1st Jan change | Capi. | |
---|---|---|
+63.30% | 12.21M | |
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07